Weight‐loss response to naltrexone/bupropion is modulated by the Taq1A genetic variant near DRD2 ( rs1800497 ): A pilot study

Authors:

Abstract
Naltrexone/bupropion (NB) is a US Food and Drug Administration‐approved antiobesity medication. Clinical trials have shown variable weight loss, with responders and non‐responders. NB is believed to act on central dopaminergic pathways to suppress appetite. The Taq1A polymorphism near DRD2 (rs1800497) is associated with the density of striatal dopamine D2 receptors, with individuals carrying the A allele (AA or AG; termed A1+) having 30%‐40% fewer dopamine binding sites than those who do not carry the A allele (GG; termed A1‐). We performed a pilot study to assess the association of the rs1800497 ANKK1 c.2137G > A (p.Glu713Lys) variant with weight loss with NB treatment in 33 subjects. Mean (SD) weight loss was 5.9% (3.2%) for the A1+ genotype group (n = 15) and 4.2% (4.2%) for the A1‐ genotype group (n = 18). The mean weight loss for the A1+ genotype group was significantly greater than the predefined clinically significant 4% weight‐loss target (one‐sample t‐test, P = .035), whereas the mean weight loss for the A1‐ genotype group was not ( P = .85). Individuals with the A1+ genotype appear to respond better to NB than A1‐ individuals.

This publication has 19 references indexed in Scilit: